carvedilol has been researched along with Benign Neoplasms in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Advances in cancer treatment have greatly improved survival rates of children with cancer." | 2.48 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. ( Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL, 2012) |
| "Moreover, stratified by cancer site, treatment with carvedilol in the carvedilol cohort resulted in significantly lower incidence of stomach and lung cancers than in the noncarvedilol cohort." | 1.42 | Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study. ( Kao, CH; Lin, CL; Lin, CS; Lin, WS, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bonuccelli, G | 3 |
| Sotgia, F | 3 |
| Lisanti, MP | 3 |
| Ozkalayci, F | 1 |
| Tanboga, IH | 1 |
| Pino, EHM | 1 |
| Weber, MN | 1 |
| de Oliveira, LO | 1 |
| Vieira, LC | 1 |
| Dos Santos, KHS | 1 |
| Liu, IP | 1 |
| Gomes, HM | 1 |
| Trindade-Gerardi, AB | 1 |
| Moreira, JCF | 1 |
| Gerardi, DG | 1 |
| Kheiri, B | 1 |
| Abdalla, A | 1 |
| Osman, M | 1 |
| Haykal, T | 1 |
| Chahine, A | 1 |
| Ahmed, S | 1 |
| Osman, K | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Bhatt, DL | 1 |
| Abuosa, AM | 1 |
| Elshiekh, AH | 1 |
| Qureshi, K | 1 |
| Abrar, MB | 1 |
| Kholeif, MA | 1 |
| Kinsara, AJ | 1 |
| Andejani, A | 1 |
| Ahmed, AH | 1 |
| Cleland, JGF | 1 |
| Saeidnia, S | 1 |
| Abdollahi, M | 1 |
| Lin, CS | 1 |
| Lin, WS | 1 |
| Lin, CL | 1 |
| Kao, CH | 1 |
| Cardinale, D | 1 |
| Colombo, A | 1 |
| Lamantia, G | 1 |
| Colombo, N | 1 |
| Civelli, M | 1 |
| De Giacomi, G | 1 |
| Rubino, M | 1 |
| Veglia, F | 1 |
| Fiorentini, C | 1 |
| Cipolla, CM | 1 |
| Harake, D | 1 |
| Franco, VI | 1 |
| Henkel, JM | 1 |
| Miller, TL | 1 |
| Lipshultz, SE | 1 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Takara, K | 1 |
| Sakaeda, T | 1 |
| Okumura, K | 1 |
| Kalay, N | 1 |
| Basar, E | 1 |
| Ozdogru, I | 1 |
| Er, O | 1 |
| Cetinkaya, Y | 1 |
| Dogan, A | 1 |
| Inanc, T | 1 |
| Oguzhan, A | 1 |
| Eryol, NK | 1 |
| Topsakal, R | 1 |
| Ergin, A | 1 |
| Noori, A | 1 |
| Lindenfeld, J | 1 |
| Wolfel, E | 1 |
| Ferguson, D | 1 |
| Bristow, MR | 1 |
| Lowes, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy[NCT06103279] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.[NCT03392740] | Phase 4 | 200 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| Early Detection of Late Anthracycline Induced Cardiotoxicity in Survivors of Childhood Malignancy[NCT04852965] | 208 participants (Anticipated) | Observational | 2021-10-20 | Recruiting | |||
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for carvedilol and Benign Neoplasms
| Article | Year |
|---|---|
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Topics: Anthracyclines; Antioxidants; Cardiotoxicity; Carvedilol; Heart Diseases; Humans; Neoplasms | 2018 |
Toxicological and pharmacological concerns on oxidative stress and related diseases.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; B | 2013 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Ant | 2012 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance.
Topics: Adrenergic beta-Antagonists; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfam | 2004 |
5 trials available for carvedilol and Benign Neoplasms
| Article | Year |
|---|---|
Evaluation of cardioprotective effects of carvedilol in dogs receiving doxorubicin chemotherapy: A prospective, randomized, double-blind, placebo controlled pilot study.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Carvedilol; Diastole; Dog Diseases; Dogs; | 2021 |
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Topics: Adult; Antibiotics, Antineoplastic; Antioxidants; Carvedilol; Double-Blind Method; Doxorubicin; Fema | 2018 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antin | 2006 |
4 other studies available for carvedilol and Benign Neoplasms
| Article | Year |
|---|---|
Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.
Topics: Biological Products; Carvedilol; Cell Line, Tumor; Glycolysis; Humans; Neoplasms; Neoplastic Stem Ce | 2022 |
Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.
Topics: Biological Products; Carvedilol; Cell Line, Tumor; Glycolysis; Humans; Neoplasms; Neoplastic Stem Ce | 2022 |
Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.
Topics: Biological Products; Carvedilol; Cell Line, Tumor; Glycolysis; Humans; Neoplasms; Neoplastic Stem Ce | 2022 |
Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.
Topics: Biological Products; Carvedilol; Cell Line, Tumor; Glycolysis; Humans; Neoplasms; Neoplastic Stem Ce | 2022 |
Strategies to Prevent Cardiotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Neoplasms; | 2019 |
Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cohort Studies; Female; Follow-Up | 2015 |
Beta-blockade in adriamycin-induced cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antineoplastic Agents; Carbazoles; Cardiomyopathies; Cardi | 2000 |